Key points from article :
LinkGevity, a company based at Babraham Research Campus and affiliated with the University of Cambridge, has been selected for the prestigious KQ Labs Programme at the Francis Crick Institute. The company focuses on age-related diseases and longevity, with its leading drug, an anti-necrotic therapeutic, set for clinical trials targeting kidney disease and accelerated ageing. The programme offers funding and access to a global scientific network, helping LinkGevity move forward with its research.
The company was also chosen as one of 12 global participants in the NASA/Microsoft Space-Health Program. This recognition comes from the potential of its anti-necrotic therapeutic to prevent accelerated ageing and tissue degeneration in astronauts. The drug’s ability to slow down ageing could have major implications for both space travel and medical treatments on Earth.
The KQ Labs Programme would be essential in advancing their clinical trials. She pointed out that kidney disease, the ninth leading cause of death worldwide, provides a model to study ageing more broadly.
The company operates based on its Blueprint Theory of Ageing, developed by Carina in collaboration with experts. This theory helps identify and target key molecular pathways that drive age-related conditions. By intervening in these pathways with broad-spectrum therapeutics, LinkGevity aims to slow or stop age-related decline.
Their flagship drug, Anti-Necrotic™, targets necrosis, a process linked to tissue damage and ageing. It has already secured funding from Horizon Europe and the UK government. This support reflects confidence in its potential to treat multiple age-related diseases.
LinkGevity plans to launch its first clinical trial later this year, focusing on kidney disease and associated ageing. If successful, the company aims to expand its research to other conditions related to ageing, potentially leading to significant breakthroughs in longevity and disease prevention.
